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Abstract
Liver transplantation (LT) for hepatocellular carcinoma is effective for selected patients. LT for other malignancies like
cholangiocarcinoma (CCA), hepatoblastoma (HB), hepatic epithelioid hemangioepithelioma (HEHE), angiosarcoma (AS),
and neuroendocrine tumors (NET) is being defined. For CCA, series that did not emphasize highly selected early stage
disease and neoadjuvant or adjuvant chemoradiation had an average 5-year survival of 10%. However, emphasizing
neoadjuvant radiation and chemosensitization in operatively confirmed stage I or II hilar CCA has led to improved 5-year
survival, up to 82%. LT is indicated under strict research protocols at selected centers, for patients with early stage CCA
and anatomically unresectable (Bismuth type IV) lesions. HB is typically sensitive to cisplatin-based chemotherapy. LT
plays a role as primary surgical therapy for those individuals in whom tumors remain unresectable after chemotherapy or as
rescue therapy for those who are incompletely resected, recur after resection, or develop hepatic insufficiency after
chemotherapy and/or resection. Long-term survival is reported at 5888%. HEHE is a multifocal tumor that lies
somewhere between benign hemangiomas and malignant AS. The extensive multifocal nature makes resection difficult and
LTan attractive option. Series on LT for HEHE report overall survival of 7178% at 5 years. However, AS is an aggressive
tumor and LT is contraindicated. For NET, resection of the primary tumor and all gross metastatic disease is reported to
provide 5-year survival of 7085%. LT has been employed for some patients for unresectable tumors or for palliation of
medically uncontrollable symptoms with 5-year survival reported between 36% and 80%.
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Introduction
Liver transplantation (LT) has become an effective
and widely accepted treatment for hepatocellular
carcinoma (HCC), providing good long-term dis-
ease-free and overall survival as appropriate criteria
evolved to select patients. The indications for LT have
also developed for less common hepatic tumors,
achieving acceptable results, perhaps surrounded by
more controversy and evolving later. These other
malignancies including cholangiocarcinoma, hepato-
blastoma, hepatic epithelioid hemangioendothelioma,
angiosarcoma, and metastasis from neuroendocrine
tumors, all of which are the topic of this article, occur
more frequently in non-cirrhotic liver than HCC.
This fact sometimes makes obtaining a graft at an
appropriate time from an oncologic point of view
more difficult than for HCC. Understanding treat-
ment options, the pathology of various tumors, the
tumor stage, size, number and location, the patient’s
underlying condition, and the resources available are
keys to selecting the optimal treatment choice for each
patient. This article focuses on the transplantation
option.
Cholangiocarcinoma
Cholangiocarcinoma (CCA) is the second most
common primary hepatobiliary malignancy in the
United States [1]. Worldwide, it accounts for 3% of
all primary gastrointestinal malignancies and 10% of
primary hepatobiliary malignancies [2]. CCA is
notoriously difficult to treat as it often presents in
advanced stages where it is not amenable to resection.
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Reports of 5-year survival following resection range
from 8% to 44% [3].
With few long-term survivors after resection, at-
tempts at cure of CCA were made in the early LT
experience. One early aggregation of patients in 1991
from the University of Cincinnati tumor registry
revealed 2- and 5-year survival rates of 30% and
17%, respectively [4]. This was confirmed in 2000 by
the same group examining the results of 207 patients
undergoing liver transplantation for cholangiocarci-
noma. This revealed an overall 1-, 2-, and 5-year
survival rate of 72%, 48%, and 23%, respectively [5].
These series did not analyze peripheral and central
CCA separately.
The Hannover experience reported in 1989 showed
similar results, with only 1 of 10 patients with
intrahepatic cholangiocarcinoma and 10 of 20 pa-
tients with proximal bile duct cholangiocarcinomas
surviving to 1 year [6]. A series out of the University
of Pittsburgh examining 20 patients transplanted for
intrahepatic CCA identified a 5-year survival rate of
only 18% [7]. The King’s College experience reported
similar results with almost universal disease recur-
rence and death within 3 years of transplantation for
patients with both peripheral and central CCA [8].
The results of these early series, which did not
emphasize highly selected early stage disease and
neoadjuvant or adjuvant radiation and chemotherapy,
had an average 1-, 3-, and 5-year survival of 43%,
30%, and 10%, respectively [9]. A more recent review
of Spanish centers identified a 5-year survival of 30%
for patients transplanted with hilar CCA and 42% for
peripheral CCA. A summary of selected series is given
in Table I. These studies, among others, established
CCA as a poor indication in general for transplanta-
tion due to high disease recurrence with few long-
term survivors. In addition, the poor results with
transplantation for peripheral CCA have not exceeded
conventional surgery, leading to the abandonment of
transplantation for known peripheral CCA.
Note that in the study by Goss et al., incidental
CCAs treated with transplantation had a 5-year
survival of 83% (incidental CCA were lesionsB/1
cm that were discovered on pathologic examination of
the explanted liver) [10]. However, patients in this
same study with known CCA had a 5-year survival of
0%. This observation helped stimulate a more selec-
tive approach to transplantation for CCA.
Highly selected patients with CCA found in the
study by DeVreede et al. demonstrated an 80% 5-year
survival [11]. Ten of the 11 patients transplanted were
stage I and II patients. They all underwent external
beam irradiation plus bolus 5-fluorouracil (5-FU),
followed by brachytherapy with iridium plus 5-FU
infusion, followed by exploratory laparotomy, and
finally a continuous 5-FU infusion until transplanta-
tion. Sudan et al., using a protocol of intense
brachytherapy and 5-FU, reached a 3- and 5-year
survival of 45% in 11 transplanted patients [12]. And
more recently, the Mayo group reported a protocol
utilizing neoadjuvant external beam radiation therapy,
chemosensitization with infusional 5-FU and oral
capecitabine, and intraluminal brachytherapy. Eligible
patients had to have operatively confirmed, stage I or
II unresectable hilar CCA or CCA arising in the
setting of primary sclerosing cholangitis prior to
orthotopic liver transplantation. Of the 38 patients
undergoing transplantation, improved survival was
demonstrated; 92% at 1 year, 82% at 3 years, and
82% at 5 years. Additionally, 1-, 3-, and 5-year
recurrence rates were also improved at 0%, 5%, and
12%, respectively [13]. The studies shown in Table II
indicate that LT for early stage hilar CCA in selected
individuals can be effective and should be considered
as part of a research protocol in certain centers.
Hepatoblastoma
Hepatoblastoma (HB) is the most common primary
malignant hepatic tumor in the pediatric population,
with the incidence peaking in the first 3 years of life.
Table I. Survival after liver transplantation for cholangiocarcinoma.
Survival
Author Year Institution n 1-year 2-year 3-year 5-year
O’Grady et al. [38] 1988 King’s College 26 34% 15% 8% 5%
Ringe et al. [6] 1989 Hannover 30 38% 32%  14%
Penn [4] 1991 Cincinnati registry 109  30%  4%
Nashan et al. [39] 1996 Hannover 10 30%   10%
Goss et al. [10] 1997 UCLA (known) 4 33% 33%  0%
Goss et al. [10] 1997 UCLA (incidental) 10 90%  83% 83%
Iwatsuki et al. [40] 1998 Pittsburgh 27 60% 36% 36% 36%
Bismuth [41] 2000 Paul Brousse 9   33% 
Meyer et al. [5] 2000 Cincinnati registry 207 72% 48%  23%
Shimoda et al. [42] 2001 UCLA 25 71%  35% 
Robles et al. [43] 2004 Spanish centers (hilar) 36 82%  53% 30%
Robles et al. [43] 2004 Spanish centers (peripheral) 23 77%  65% 42%
Ghali et al. [44] 2005 Canadian centers (incidental) 10 90%  30% 
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Approximately 60% of patients are unresectable at the
time of diagnosis [14]. These tumors are typically very
sensitive to cisplatin-based chemotherapy. Therefore,
the cornerstone of therapy is neoadjuvant chemother-
apy in an attempt to decrease tumor bulk to allow
patients to become candidates for resection. When
followed after surgical resection, an 80% 510-year
disease-free survival has been demonstrated [15]. LT
plays a role as primary surgical therapy for those
individuals afflicted with HB in whom tumors are
unresectable after chemotherapy. Additionally, LT
plays a role as rescue therapy for patients who are
incompletely resected, recur after resection, or de-
velop hepatic insufficiency after chemotherapy and/or
resection.
Otte et al. [16] reviewed the world experience with
LT for HB, collecting data from 24 centers (12 in
North America, 10 in Europe, 1 in Japan, and 1 in
Australia). They found that the overall survival at
6 years post transplant was 82% for primary trans-
plant recipients and 30% for rescue transplant reci-
pients. These positive results for LT for HB have been
supported by subsequent studies. A smaller series
from the University of Cincinnati had an 88% overall
survival rate with the lone death occurring 7 years
after rescue transplantation from post-transplant lym-
phoproliferative disorder [14]. A recent review of the
United Network for Organ Sharing database of 135
patients undergoing LT for HB also demonstrated
good long-term results. The reported 1-, 5-, and
10- year survival rate was 71%, 61%, and 58%,
respectively [17]. The largest single institution series
of living donor liver transplantation for HB is from
Kyoto University Hospital in Japan [18]. A 72%
overall survival was demonstrated in 14 patients
(7 primary transplant, 7 rescue) at a median follow-
up of 42 months. Results of selected series are shown
in Table III. Based on these reports and others, LT for
HB has become a widely accepted indication for LT if
the tumor is unresectable after chemotherapy or as a
rescue therapy for residual disease after resection or
for hepatic insufficiency after chemotherapy and/or
resection.
Hepatic epithelioid hemangioendothelioma and
angiosarcoma
Hepatic epithelioid hemangioendothelioma (HEHE)
is a rare, multifocal tumor arising from the vascular
endothelium, predominantly effecting females (1.6:1).
HEHE is an enigmatic tumor with unpredictable
malignant behavior that lies somewhere in the spec-
trum between benign hemangiomas and malignant
angiosarcomas (AS) [19]. Due to the multifocal
nature of disease, HEHE can often be misdiagnosed
as metastatic disease. The lesions are bilobar in almost
all cases and number an average of 15 or more [20].
Chemotherapy and radiation appear to offer little
benefit. Some patients have had long-term survival
with no therapy [21], while others succumb within
months from rapid progression. Distinction between
these two clinical courses is difficult to predict,
necessitating intervention. Resection is therefore in-
dicated but the extensive multifocal nature of the
disease can make surgical resection quite difficult and
has made LT the more attractive option.
Most series on LT for HEHE are small, but show
favorable outcomes. One of the larger series to date
includes 16 patients who underwent transplantation
for HEHE at the University of Pittsburgh. Overall
survival was 100%, 88%, and 71% at 1, 3, and
5 years. Disease-free survival was 81%, 69%, and
60% at 1, 3, and 5 years, respectively [22]. Interest-
ingly, the presence of extrahepatic disease at the time
of transplantation did not effect survival time. A series
from Heidelberg of three patients who received LT for
HEHE (two cadaveric grafts, one living donor graft)
reported no deaths with a follow-up of 13, 13, and
151 months, respectively [23]. Finally, the European
Liver Transplant Registry contains 51 patients that
were transplanted for HEHE with a 5- and 10-year
survival of 87% and 78%, respectively [20]. There
Table III. Summary of selected results of liver transplantation for
hepatoblastoma.
Center Period n
Overall
survival (%)
Pittsburgh [45] 19891998 12 83
Omaha [16] 19861999 10 70
UCLA [16] 19842001 16 75
Brussels [16] 19872001 10 70
Birmingham, UK [46] 19912000 14 79
London, UK [47] 19922001 11 100
Baylor [48] 19842000 9 66
SIOPEL-1 [16] 19902001 12 66
UNOS review [17] 19872004 135 66
Table II. Survival after liver transplantation for cholangiocarcinoma in which early stage disease and neoadjuvant or adjuvant radiation and
chemotherapy are emphasized.
Survival
Author Year Institution n 1-year 2-year 3-year 5-year
DeVreede et al. [11] 2000 Mayo 11 100% 100% 100% 80%
Sudan et al. [12] 2002 Nebraska 11 55% 45% 45% 
Rea et al. [13] 2005 Mayo 38 92%  82% 82%
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was no difference in survival from the presence of
extrahepatic disease in adults, although some required
additional pulmonary resections. These reports and
others have made HEHE an acceptable indication for
LT, even in the face of extrahepatic disease.
The vascular endothelium is also the point of
origination for AS. Unlike HEHE, however, AS is a
very aggressive tumor and is a contraindication to LT.
The outlook for patients transplanted in which AS is
found incidentally is ominous. One report from the
United Network for Organ Sharing database on seven
transplant patients in whom AS was incidentally
discovered demonstrated a mean survival of 262
days [24]. There were 17 patients in the European
Liver Transplant Registry who had undergone trans-
plantation for angiosarcoma with a median survival of
only 7 months [20]. Reports like this have led to
abandonment of liver transplant in the setting of AS.
It is an absolute contraindication.
Neuroendocrine tumors (NET)
Variable 5-year survival for untreated liver metastasis
from NET has been reported, centering on 3040%,
and for carcinoid tumors a slightly more favorable
prognosis [25]. Because these tumors are character-
istically relatively slow growing and treatment re-
sponse rates are quite different from a comparable
tumor load of other types of metastasis, these patients
deserve careful and thoughtful consideration of ag-
gressive medical and surgical therapy. For example,
functional hormonal blockade and/or tumor debulk-
ing or ablation can produce improved quality and
length of life by decreasing the levels of circulating
hormones produced by the tumor and the resulting
symptoms.
It is commonplace for liver metastases of NET to be
bilobar and patients with NET can have a miliary
pattern of disease and often present with distant
disease. Therefore, only about 1020% of patients
will be candidates for resection, and even then total
resection is not often accomplished. In general,
palliative resection of hepatic metastases is believed
to be a worthwhile endeavor if 8090% of the gross
hepatic tumor mass can be successfully resected and
the surgical risk is very low [26]. Symptomatic
improvement can be expected in the majority of these
patients and the duration of the clinical response is felt
to be inversely proportional to the amount of residual
tumor following resection [27,28].
LT has been employed for some patients for
unresectable tumors or for palliation of medically
uncontrollable symptoms. This is currently the only
metastatic indication for LT [29]. A total of 103
patients reported in the world literature transplanted
for metastatic NET were reviewed in 1998 by Lehnert
[30]. The 2- and 5-year survival rates were 60% and
47%, respectively. Factors associated with worsened
survival on multivariate analysis were age/50 years
and combined upper abdominal exenteration. Other
factors that have been proposed in selecting patients
for transplantation are progression of liver tumors, the
absence of extrahepatic disease proven over a 6-month
period, and excessive hormonal symptoms refractory
to medical therapy [31].
Florman et al. [32] reported an overall survival of
73% and 36% at 1 and 5 years, respectively, with a
mean follow-up of 34 months. Lang et al. [33]
reported an actuarial survival of 75%, with a median
follow-up of 55 months; 58% of these patients
developed recurrence. Two other publications de-
monstrated good short-term survival, each 89% at
1 year [34,35]. These results are summarized in Table
IV. These authors suggest that cure for metastatic
NET to the liver is unlikely. Furthermore, due to
overall reported results, they recommend that liver
transplantation should be withheld until all other
avenues of treatment have been explored and deemed
unsuccessful. Sutcliffe et al. [29] recommend using
the Milan criteria for assessing the suitability of LT
in the setting of metastatic NET, although these
criteria have not been validated. Furthermore,
they suggest that results could also be improved if
primary resection is undertaken prior to transplanta-
tion and if patients are transplanted early in their
clinical course when the presence of extrahepatic
disease is less likely.
Primary NET of the liver are even rarer than their
metastatic counterparts. There have been fewer than
60 reported cases in the world literature, with the
largest series to date consisting of 8 patients, 2 of
whom required transplantation due to unresectable
disease [36]. Both of these patients had successful
outcomes with survival of 45 and 95 months, respec-
tively.
Table IV. Results of selected series for liver transplantation for metastatic neuroendocrine tumors.
Reference Year n
1-year
survival (%)
5-year
survival (%)
Actuarial 5-year
disease-free survivors
Lang et al. [33] 1997 12 83 83 1
Olausson et al. [34] 2002 9 89  0
Rosenau et al. [35] 2002 19 89 80 3
Florman et al. [32] 2004 11 73 36 1
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Metastatic disease
Metastatic disease to the liver is very rarely an
indication for LT, except in the setting of NET.
However, in 2005, successful long-term outcome
following LT for metastatic gastrointestinal stromal
tumors in two patients was reported [37]. Both
patients were alive without evidence of recurrence at
48 and 69 months, respectively.
Summary
In conclusion, LT for early stage hilar CCA in
selected individuals can be effective and should be
considered an indication for transplantation as part of
a research protocol in certain centers following
neoadjuvant chemoradiation.
For HB, the role of LT is twofold. First, transplan-
tation is reserved for patients who are still unresect-
able after neoadjuvant therapy. Second, LT plays a
role as rescue therapy for patients who are incomple-
tely resected, recur after resection, or develop hepatic
insufficiency after chemotherapy and/or resection.
HEHE is an acceptable indication for LT. Transplan-
tation is indicated for patients even with extrahepatic
disease, at least in adults. Angiosarcoma is an absolute
contraindication to LT. Neuroendocrine tumors,
whether metastatic or arising from the liver, can be
treated with LT when unresectable or when medical
management of symptoms cannot be achieved. Best
results will be achieved with patients ageB/50 years,
primary tumor completely resected; absence of extra-
hepatic disease proven over a 6-month period; and
excessive hormonal symptoms refractory to medical
therapy.
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